Trial Profile
Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Dec 2014 Status changed from active, no longer recruiting to completed.